Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 2/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.30 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29937218 | 1.00 | NUDT1 (0.33) | NUDT1PIM1ESR1ESR2RPS6KA2 | |
| SCHEMBL18614436 | 0.80 | PIK3CA (0.33) | NUDT1 | |
| SCHEMBL29344237 | 0.78 | ESR1 (0.30) | ESR1ESR2 | |
| SCHEMBL25547745 | 0.78 | NUDT1 (0.41) | NUDT1RPS6KA2 | |
| SCHEMBL24785873 | 0.74 | NUDT1 (0.34) | NUDT1RPS6KA2 | |
| SCHEMBL29301859 | 0.74 | NUDT1 (0.34) | NUDT1RPS6KA2 | |
| SCHEMBL18614398 | 0.70 | NUDT1 (0.44) | NUDT1ESR1ESR2RPS6KA2 | |
| SCHEMBL29297683 | 0.67 | NUDT1 (0.34) | NUDT1RPS6KA2 | |
| SCHEMBL25914949 | 0.67 | NUDT1 (0.34) | NUDT1RPS6KA2 | |
| SCHEMBL288526 | 0.67 | NUDT1 (0.41) | NUDT1RPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | NUDT1 1534/4885PIM1 1261/4885ESR1 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.